New Observations on a Low-Grade Diffusely Infiltrative Tumour, SMARCB1 Mutant, Arguing for a New Tumour Type.

Neuropathol Appl NeurobiolSep 8, 2026
Case ReportOncology (Medical)Pathology (Anatomic & Clinical)Neurology

Alice Métais, Giorgia Antonia Simboli, Marc Barritault et al.

✦ AI-curated · Sources linked

Case in brief

This report details two cases of low-grade diffusely infiltrative tumour (LGDIT) in an 18-year-old and a 50-year-old male, both presenting with supratentorial lesions. Histological examination revealed characteristic rhabdoid features on a myxoid-collagenous background, alongside complete INI1 loss. Genetic analysis confirmed homozygous SMARCB1 deletion, supporting the classification of LGDIT as a distinct CNS tumour type.

Diagnostic / clinical pearl

Clinicians should recognize the distinct histological and genetic features of low-grade diffusely infiltrative tumours, particularly the significance of SMARCB1 mutations and INI1 loss in diagnosis.

Why it matters

The identification of LGDIT as a provisional CNS tumour type may influence future diagnostic and therapeutic approaches in neuro-oncology.

Source

PubMed · PMID 42703099

Published in Neuropathol Appl Neurobiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.